What is the main difference between AbbVie and Johnson & Johnson?

The main difference is that AbbVie focuses on biopharmaceuticals with a higher dividend yield, while Johnson & Johnson is more diversified across healthcare sectors and has a longer dividend growth streak.

How many consecutive years of dividend increases does each company have?

AbbVie has 52 consecutive years of dividend increases, while Johnson & Johnson has 66 years.

Which company offers a higher dividend yield?

AbbVie offers a higher dividend yield of approximately 4.5%, compared to about 3% for Johnson & Johnson.

What are the main risks for AbbVie stock?

The main risk is AbbVie's heavy reliance on Humira, which faces biosimilar competition, potentially impacting revenue and earnings.

What are the main risks for Johnson & Johnson stock?

The main risk is ongoing litigation related to talc products, which could result in large settlements and impact cash flows.

Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson?

This article compares AbbVie (ABBV) and Johnson & Johnson (JNJ), two healthcare giants with a combined 118-year history of consecutive dividend increases, to help investors decide which is the safer choice for income.

AbbVie (ABBV) and Johnson & Johnson (JNJ) are two of the most prominent dividend stocks in the healthcare sector, boasting a combined 118 years of consecutive dividend increases. This analysis compares the two to help investors determine which is the safer bet.

Key Comparison

Metric	AbbVie (ABBV)	Johnson & Johnson (JNJ)
Dividend Growth Streak	52 consecutive years	66 consecutive years
Sector	Healthcare (Biopharma)	Healthcare (Diversified)
Current Dividend Yield	~4.5%	~3%

Strengths

AbbVie

Higher Yield: Offers a higher dividend yield compared to JNJ.
Strong Growth: Benefits from a robust drug portfolio including Humira, Skyrizi, and Rinvoq.
Clear Focus: Concentrated on biopharmaceuticals, which can drive faster growth.

Johnson & Johnson

Greater Diversification: Operates across pharmaceuticals, medical devices, and consumer health, reducing risk.
Longer History: 66 years of consecutive dividend increases, signaling stability.
Financial Strength: High credit rating and ability to weather economic downturns.

Risks

AbbVie: Heavy reliance on Humira, which faces biosimilar competition.
Johnson & Johnson: Ongoing litigation related to talc products, which could impact cash flows.

What This Means for Investors

The choice depends on individual goals. For higher yield and tolerance for risk, AbbVie may be suitable. For stability and diversification with a long dividend history, Johnson & Johnson is a solid option.